Long-term impact of pneumococcal conjugate vaccines on invasive disease and pneumonia hospitalizations in indigenous and non-indigenous Australians
Background Universal pneumococcal conjugate vaccine (PCV) programs began in Indigenous Australian children in 2001 and all children in 2005, changing to 13-valent PCV (PCV13) in 2011. We used laboratory data for invasive pneumococcal disease (IPD) and coded hospitalizations for noninvasive pneumococcal community-acquired pneumonia (PnCAP) to evaluate long-term impact. Methods Annual incidence (per 100 000 population) was calculated for age-specific total IPD, PCV13 non-C7-valent PCV (PCV7)...[Show more]
|Collections||ANU Research Publications|
|Source:||Clinical Infectious Diseases|
|ciz731.pdf||1.15 MB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.